02:09:09 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-05 Kvartalsrapport 2024-Q3
2024-08-20 Kvartalsrapport 2024-Q2
2024-05-22 Ordinarie utdelning OSSD 0.00 SEK
2024-05-21 Årsstämma 2024
2024-05-14 Kvartalsrapport 2024-Q1
2024-02-06 Bokslutskommuniké 2023
2023-11-21 Kvartalsrapport 2023-Q3
2023-10-16 Extra Bolagsstämma 2023
2023-08-22 Kvartalsrapport 2023-Q2
2023-06-01 Ordinarie utdelning OSSD 0.00 SEK
2023-05-31 Årsstämma 2023
2023-05-23 Kvartalsrapport 2023-Q1
2023-02-21 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-06-03 Ordinarie utdelning OSSD 0.00 SEK
2022-06-02 Årsstämma 2022
2022-05-24 Kvartalsrapport 2022-Q1
2022-02-22 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-20 Ordinarie utdelning OSSD 0.00 SEK
2021-05-19 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-04-09 Extra Bolagsstämma 2021
2021-02-11 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-19 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning OSSD 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
OssDsign är verksamt inom läkemedelsbranschen. Bolaget är idag specialiserat inom forskning och utveckling av läkemedel för bendefekter. Läkemedlena baseras på biokeramiskt material vars sammansättning används för att förbättra läkningsprocessen i olika fall av patientskador. Produkterna vidaresäljs som implantat och används huvudsakligen för behandling av skallskador.
2021-07-08 13:00:00

Uppsala, Sweden, 13:00 CET, 8 July 2021 - OssDsign AB has been selected to exhibit Cranial PSI, a patient-specific 3D-printed implant using OssDsign's personalized bone replacement technology, at the Vizient Innovative Technology Exchange. Vizient, Inc (https://www.vizientinc.com/), the nation's largest member-driven health care performance improvement company, will hold the Exchange virtually Sept. 21-23.

The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient's member hospitals and subject matter experts who serve on their supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety or drives incremental improvements to health care delivery or business models.

Cranial PSI is designed using state-of-the-art technology in material science and advanced 3D printing and represents an innovative approach to patient-specific reconstruction of skull defects. Based on a biocompatible calcium phosphate composition, OssDsign Cranial PSI provides a solution for a variety of needs associated with skull reconstruction. Following the thorough application process, OssDsign has been selected to attend the Vizient Innovative Technology Exchange. Vizient serves more than half of the healthcare organizations across the United States including 97 percent of the nation's academic medical centers. Innovative Technology contracts are awarded based on recommendations of Vizient's member-led councils who, following the annual Exchange, review select products that have the potential of delivering innovative improvements to health care.

"We are excited over the significant potential sales opportunity Vizient's event represents and that we have been selected to showcase our unique solution for reconstruction of cranial defects to members of its network. We see this as a clear acknowledgment of the high standard of innovation in Cranial PSI and its significant potential in increasing patients' quality of life as well as reducing societal costs," comments Morten Henneveld, CEO, OssDsign AB.

"The Exchange is an exciting part of the Vizient Innovative Technology Program, which results in Innovative Technology contract awards for the qualified products. This signals health care providers of a product's unique qualities," said Debbie Archer (https://newsroom.vizientinc.com/debbie-archer-mba.htm), procurement compliance director, Vizient.  "With only a select number of suppliers invited to demonstrate their products, it's an honor to be invited."

The annual Innovative Technology Exchange is part of Vizient's Innovative Technology Program (https://www.vizientinc.com/our-solutions/supply-chain-solutions/supply-chain-programs/innovative-technology-program) that includes product review of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has received over 2,800 technology submissions as part of its Innovative Technology Program.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company's Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign
OssDsign's vision is to provide regenerative solutions to all patients with cranial or spinal bone defects, so they can b e restored and healed as naturally as possible. Driven by a commitment to give patients back the lives they deserve, OssDsign collaborates with surgeons to engineer better healing by integrating biomaterials with clinical design. Headquartered in Sweden, OssDsign supplies hospitals worldwide with implants for use in cranial reconstructions and other orthopaedic surgery applications.